Incyclix Bio, LLC announced that it has received $46.25 million in funding from a group of investors

On the April 8, 2026, Incyclix Bio, LLC closed the transaction. The company amended the terms of the transaction. The company has received $5 million in its third and final tranche.

The transaction included participation from new investor Hatteras Venture Partners VII, LP, a fund managed by Hatteras Venture Advisors VI, LLC. The company received a total of $46.25 million in the transaction. As a part of this transaction, Hatteras partner Kseniya Simpson, Ph.D., will join the company?s board of directors and Hatteras general partner Christy Shaffer, Ph.D., will join as a board observer.